Wolfe Research Initiates Coverage on Palisade Bio and Avalo Therapeutics with Strong Buy Calls

Wolfe Research: PALI “Outperform” ($7) eyes 2027 ulcerative colitis trial; AVTX “Outperform” ($48) waits May LOTUS Phase 2 readout.